AI Article Synopsis
- A new anti-emetic agent called indisetron hydrochloride was developed in Japan, showing similar receptor affinity to existing treatments.
- Indisetron demonstrated significantly stronger antagonistic activity against the 5-HT3 receptor than granisetron and ondansetron, suggesting superior effectiveness in preventing nausea caused by chemotherapy.
- Clinical trials, including phase III studies, indicated that indisetron is as effective or potentially more effective than other 5-HT3 receptor antagonists for managing chemotherapy-induced nausea and vomiting.
Article Abstract
Recently, an anti-emetic agent, indisetron hydrochloride was developed in Japan. In the pre-clinical studies, it showed almost similar affinity to 5-HT3 receptor as those developed before. Indisetron reduced 2-methyl-5-serotonin (HT)-induced bradycardia. The 5-HT3 antagonistic activity was over 20 times more than that of granisetron or ondansetron, indicating the excellent anti-emetic activity against anticancer drug induced vomiting. After phase I and II clinical studies, phase III studies consisting of a comparative double-blind randomized clinical trial (comparing with ondansetron) and open clinical trials, the effectiveness and safety profiles of this indisetron were clearly shown. From these studies, it was considered that indisetron seemed to be equally or more effective against chemotherapy-induced nausea and vomiting compared with existed 5-HT3 receptor antagonists.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!